-
Posted by
Two Blokes May 16 -
Filed in
Stock
-
2 views
ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) complied with federal securities laws. On May 16, 2025, the FDA stated: “Given that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret. While CR indicates drug activity of UGN-102, it is unclear whether the observed DOR can be attributed to the investigational product or instead reflects the natural history of the disease.” Following this news, the price of the Company's stock dropped.
